OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Nemours Children's Hospital is now offering Lyfgenia gene therapy. The treatment aims to reduce pain crises and hospital visits for young patients.
SINGAPORE, SG / ACCESS Newswire / March 20, 2026 / Immortal Dragons, a $40M longevity fund headquartered in Singapore, today announced that its portfolio company Unlimited Bio has registered a Phase 1 ...
The 23-year-old man received a gene therapy transfusion Wednesday at Manning Family Children's Hospital that doctors say should cure his sickle cell disease. It’s a condition he has lived with his ...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.08711, expectations were ...
Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was ...
Vietnam Investment Review on MSN
Belief BioMed gains Macao approval for hemophilia B gene therapy
SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical ...
A new study has for the first time elucidated the gut-liver immune regulatory axis jointly maintained by intestinal commensal bacteria and the intestinal endocrine system, and uncovered the ...
SINGAPORE, SG / ACCESS Newswire / March 20, 2026 / Immortal Dragons, a $40M longevity fund headquartered in Singapore, today announced that its portfolio company Unlimited Bio has registered a Phase 1 ...
For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results